None listed
Conditions
Brief summary
Functional mitral regurgitation in patients with or without atrial fibrillation without left ventricular dysfunction and/or dilatation, namely, atrial functional mitral regurgitation (AFMR), has been increasingly recognized. It occurs in the setting of left atrial dilatation and or atrial fibrillation in patients with heart failure with preserved ejection fraction (HFpEF). However, there are very limited published data regarding therapeutic strategies of AFMR. We aim to understand the optimal therapeutic options by investigating the outcomes of previously treated patients when this concept was not well recognized.
Interventions
Patients who underwent surgery for atrial functional mitral regurgitation from January 2020 to December 2022 will be enrolled in the trial.
Patients will undergo
- Transthoracic echocardiogram (TTE)
- Electrocardiogram (ECG)
- Kansas City Cardiomyopathy Questionnaire (KCCQ-12) (approximately 20 minutes)
Patients perioperative data (type of Surgery, concomitant procedure, cardiopulmonary bypass time (CPB) time, aortic cross clamp time) will be collected retrospectively from medical records.
Sponsors
The Alfred
Eligibility
Sex/Gender
All
Age
21 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
Candidates must meet all of the following criteria to be enrolled in the study. • Is ambulatory, able and willing to comply with the study protocol and has provided written informed consent • Has undergone mitral valve surgery between January 2014 to December 2022 for AFMR.
Exclusion criteria
Candidates will be excluded from enrolment in the study if any of the following conditions apply. • Patients who have already deceased (mortality will be included in the secondary outcome).
Outcome results
None listed